Elsevier

Brain, Behavior, and Immunity

Volume 88, August 2020, Pages 71-74
Brain, Behavior, and Immunity

Short Communication
Spectrum of neuropsychiatric manifestations in COVID-19

https://doi.org/10.1016/j.bbi.2020.06.020Get rights and content

Highlights

  • Neuropsychiatric manifestations in COVID-19 positive patients.

  • Among 40,469 COVID-19 patients, 22.5% had neuropsychiatric manifestations.

  • Common neurological manifestations are headache, sleep disorders, encephalopathy.

  • Common psychiatric manifestations are anxiety, mood disorders.

Abstract

Corona Virus Disease 2019 (COVID-19) emerged in December 2019 from Wuhan, China. It typically presents with mild upper respiratory tract infection symptoms and may have life threatening complications, including acute respiratory distress syndrome, acute stroke, myocardial infarction, kidney failure, shock, and even death. Coronavirus infections are known to have neuroinvasive potential with consequent neuropsychiatric manifestations. We analyzed COVID-19 adult patients in the TriNetX database, which is a global health collaborative clinical research platform collecting real-time electronic medical records data from a network of health care organizations (HCOs) from January 20, 2020 to June 10th, 2020. 40,469 patients were diagnosed with COVID-19 among whom 9086 (22.5%) patients had neuropsychiatric manifestations. The most common neurologic manifestations included headache (3.7%) and sleep disorders (3.4%), Encephalopathy (2.3%), Stroke and transient ischemic attack (TIA) (1.0%) and 0.6% had seizures. Most common psychiatric manifestations included anxiety and other related disorders (4.6%), mood disorders (3.8%), while 0.2% patients had suicidal ideation. Early recognition and prompt management of neuropsychiatric manifestations in these patients have a potential to decrease overall morbidity and mortality.

Cited by (0)

1

Drs Nalleballe and Onteddu are co-first authors.

View Abstract